Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Input: Consider Input: Paragraph: In research looking at how much babies around the world cry in their first three months, psychologists from Britain have created the first universal charts for normal amounts of crying during that period. WATCH: Child-sized robot helps autistic kids learn social skills "Babies are already very different in how much they cry in the first weeks of life," said Dieter Wolker, who led the study at Warwick University. "We may learn more from looking at cultures where there is less crying (including) whether this may be due to parenting or other factors relating to pregnancy experiences or genetics." The highest levels of colic defined as crying more than three hours a day for at least three days a week were found in babies in Britain, Canada and Italy, while the lowest colic rates were found in Denmark and Germany. WATCH: Brain implant lets paralysed man feed himself using his thoughts On average, the study found, babies cry for around two hours a day in the first two weeks. They then cry a little more in the following few weeks until they peak at around two hours 15 minutes a day at six weeks. This then reduces to an average of one hour 10 minutes by the time they are 12 weeks old. But there are wide variations, with some babies crying as little as 30 minutes a day, and others more than five hours. The research, published in the Journal of Pediatrics, was a meta-analysis of studies covering some 8,700 babies in countries including Germany, Denmark, Japan, Canada, Italy, the Netherlands and Britain. Wolker said the new crying chart would help health workers reassure parents whether their baby is crying within a normal range in the first three months, or may need extra support. Claim: Babies cry more in UK, Canada and Italy, less in Germany, study finds.

Output: Babies cry more in Britain, Canada, Italy and Netherlands than in other countries, while newborns in Denmark, Germany and Japan cry and fuss the least, researchers said on Monday.

Input: Consider Input: Paragraph: According to the Maine Center for Disease Control, the number of syphilis cases reported in the state increased from 48 in 2016 to 84 last year. The number of national syphilis cases increased by 18 percent in between 2015 and 2016. Maine Department of Health and Human Services spokeswoman tells the Bangor Daily News the department isn't sure why syphilis has increased in recent years. Portland Public Health Center medical director Dr. Christina DeMatteo believes opioid use and waning concerns about HIV have contributed to attitudes about having unprotected sex. Public health advocates say budget cuts resulting in changes in prevention and treatment have also affected rates in the state. ___ Information from: Bangor Daily News, http://www.bangordailynews.com Claim: Maine sees increase in reported syphilis cases.

Output: Public health officials in Maine say there has been an increase in syphilis cases, mirroring a national trend.

Input: Consider Input: Paragraph: "The cost of currently available low-dose, pulsed immune suppressing drugs could have been mentioned. It would be good to know if there would be a potential cost-saving for the patient with HiCy therapy. The story does note the economics driving drug research and implications for the development of new treatments for people with difficult-to-treat chronic conditions. The suggestion that results of this study could lead to a cure for MS seems premature, especially given the small number of people involved and outcomes at 2 years; however, the story does note the limited information available for HiCy and the need for future randomized controlled trials with a larger group of patients. The story mentions the harms of treatment typically seen in patients taking the pulsed dose of cyclophosphamide, as well as side effects seen in the small group of patients in the HiCy trial. These included: nausea and hair loss and increased risk of infection. The story also mentioned that some patients' symptoms became worse before they improved. Researchers do not currently know the long-term effects of this high-dose, concentrated drug regimen. The story adequately describes the small, open-label, pilot-stage study of 9 MS patients and presents findings for the lay reader. The story appropriately notes inclusion criteria for the study (i.e. early stages of aggressive MS) and cautions that the preliminary findings may not apply to other people with different subtypes of MS. The story provides some data on study endpoints, i.e. brain lesions in 7 of 9 people improved and there was a statistically significant reduction in disability in most participants. The story does not engage in disease mongering. The story includes U.S. prevalence data and describes different forms of MS, qualifying discussion of the novel treatment with a reminder that HiCy was only tested in very debilitated patients. As mentioned in the press release accompanying this story, the study included the ""worst of the worst"" MS patients. The story includes interview with study authors and participants, as well as Dr. Richert, VP of research and clinical programs for MS Society, who puts the results of this study in perspective. The story mentions other FDA-approved treatments for MS and compares the current use of longer-term pulsed intervals of cyclophosphamide with the higher-concentrated regimenwhich lasted only 4 days and was less toxic. The story notes that this experimental delivery system was tested in people in the early stages of a particularly aggressive form of MS, and the treatment is not a long-term cure. The story mentions that high-dose cyclophosphamide (generic name for Cytoxan, Neosar, Revimmune) (HiCy) is currently being studied via clinical trials, and at this time the concentrated form of the immunosuppressant drug is limited to people in the early stages of an aggressive form of MS. The story mentions that cyclophosphamide is already used ina different dosing regimen for treatment of MS. The high-dose regimen is under study and more information about risk and efficacy is needed before it can be accepted for clinical use. The story describes the pros and cons of this new method of administering an existing drug to a subset of patients in the early stages of a particularly debilitating form of MS. The story discusses why this method of delivery may be an improvement over existing immunosuppressant drugs regimens for difficult-to-treat cases. There is similar language in the press release and news story; however, there is also some independent reporting and the story includes a perspective (MS researcher Dr. Richert) other than those of the researchers and participants from the HiCy trials." Claim: "I've gotten my life back": Hopkins reports success with MS treatment
Output: The story describes a new method of administering an existing drug to a subset of patients in the early stages of a debilitating form of Multiple Sclerosis (MS). The story discusses why this method of delivery may be an improvement over existing immunosuppressant drug regimens for difficult-to-treat MS cases. And it explains why more information about risk and efficacy of the high-dose treatment is needed before it can be accepted for clinical use. The story adequately describes the small, open-label, pilot-stage study of 9 MS patients. The story appropriately notes inclusion criteria for the study (i.e. patients in the early stages of aggressive MS) and cautions that the preliminary findings may not apply to other people with different subtypes of MS. The suggestion by a study researcher that results of this study could lead to a cure for MS seems premature, especially given the small number of people involved and outcomes at 2 years; however, the story does note the limited information available for HiCy therapy and the need for future randomized controlled trials with a larger group of patients. The story mentions the harms of treatment typically seen in patients taking the pulsed dose of cyclophosphamide, as well as side effects seen in the small group of patients in the HiCy trial. The cost of currently available low-dose, pulsed immune suppressing drugs could have been mentioned. It would be good to know if there would be a potential cost-saving for the patient with HiCy therapy. But the story does note the economics driving drug research and implications for the development of new treatments for people with difficult-to-treat chronic conditions. Overall, though, this was a solid report.